
4D Molecular Therapeutics designs and commercializes gene therapy products for unmet medical needs.
4D Molecular Therapeutics is a biotechnology company focused on designing, developing, and commercializing transformative gene therapy products for unmet medical needs. Utilizing directed evolution, the company creates new vectors for genetic medicines, aiming to address conditions that currently lack effective treatments. Their market focus includes patients with rare and severe diseases, primarily serving customers in California.
The company has made significant strides in the field of gene therapy, leveraging advanced techniques to develop innovative solutions. Their work has garnered attention in the biotechnology community, contributing to the evolving landscape of genetic medicine. Notable affiliated individuals include Erik Allison, who plays a key role in the company's operations.

Apertura Gene Therapy
aperturagtx.com

C4 Therapeutics
c4therapeutics.com

Intergalactic Therapeutics

Solid Biosciences
solidbio.com

Dnalite Therapeutics

Poseida Therapeutics
poseida.com

Sarepta Therapeutics
sarepta.com

Voyager Therapeutics

Kriya Therapeutics

Encoded Therapeutics

Regenxbio
regenxbio.com

Beam Therapeutics
beamtx.com

Excision BioTherapeutics

Dystrogen Therapeutics
dystrogen.com

Code Biotherapeutics
codebiotx.com
Companies similar to 4D Molecular Therapeutics include Apertura Gene Therapy, C4 Therapeutics, Intergalactic Therapeutics and Solid Biosciences.
4D Molecular Therapeutics was founded in 2013.
4D Molecular Therapeutics' headquarters is located in Emeryville, CA, US.
4D Molecular Therapeutics' most recent funding round was for $120M (USD) in May 2023.
As of May 4, 2023, 4D Molecular Therapeutics has raised a total of $295M (USD).
4D Molecular Therapeutics has 140 employees as of Feb 6, 2024.